Galil Medical Announces University of California Irvine (UCI) Medical Center Enrolls First Patients in Renal TRACE Registry

Share Article

Galil Medical's TRACE Renal Registry tracks the use and effectiveness of kidney cryotherapy.

Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today that UCI Medical Center enrolled their first TRACE Registry patients.

The TRACE (Tracking Renal Tumors After Cryoablation Evaluation) Registry will allow physicians and the company to follow and evaluate the use and effectiveness of cryotherapy treatment for patients with renal masses. Cryotherapy is a minimally invasive procedure using small cryoablation needles to target and freeze tumors and other suspicious masses.

“Renal cryoablation continues to be an increasingly important management strategy in the treatment of small renal cortical neoplasms. It is through well organized prospectively established multicenter studies that we will be able accurately demonstrate the safety and efficacy of kidney cryoablation procedures," said Dr. Jaime Landman, Chairman, Department of Urology, UCI Medical Center. Dr. Landman is an expert in kidney cancer and is serving as scientific advisor for the multicenter study.

Standard treatment options for renal cell cancer include active surveillance, total and partial nephrectomies, open and laparoscopic procedures. Minimally invasive ablative therapies are increasingly accepted treatment options due to favorable clinical outcomes, reduced procedural pain, nephron sparing techniques, fewer complications and faster patient recovery.

Galil Medical initiated the TRACE Registry in May 2010 and expects to enroll an estimated 250 patients across approximately ten sites in the United States, including UCI Medical Center. Martin J. Emerson, President and CEO of Galil Medical commented, “We are very pleased to have UCI join our registry as we continue on our commitment of providing robust clinical data.”    

About Galil Medical Galil Medical is a global leader in delivering innovative cryotherapy solutions. The company is addressing patient conditions across multiple physician specialties; treatment areas include conditions affecting bone, kidney, liver, lung and prostate, as well as targeted pain applications. Company offices are in Arden Hills, Minnesota; Yokneam, Israel; and London, United Kingdom. Shareholders include Thomas, McNerney & Partners, The Vertical Group, and Investor Growth Capital.

Contact information:

Martin J. Emerson
President and CEO, Galil Medical
Tel: +1 651 287 5050
Email: marty(dot)emerson(at)galilmedical(dot)com

Bill Jacqmein
Chief Technology Officer, Galil Medical
Tel: +1 651 287 5090
Email: bill(dot)jacqmein(at)galilmedical(dot)com

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bill Jacqmein

404-216-6190
Email >